Leave a little sharper than you arrived.

News, calculators, learning and daily puzzles — pick any one and leave a little further along.

Today’s puzzle

FDA-approved belzutifan + lenvatinib combo reshapes second-line kidney cancer treatment

A new standard of care has arrived for advanced kidney cancer. The FDA approved belzutifan plus lenvatinib in September 2026 for patients with advanced clear cell renal cell carcinoma (ccRCC) after prior immunotherapy, based on LITESPARK-011 trial data showing improved progression-free survival and response rates vs. cabozantinib. Experts say the approval may prompt clinicians to rethink first-line treatment sequencing strategies.

Healio · 2 min

FDA-approved once-monthly injectable Weltruza could be a game-changer for schizophrenia adherence

Healio · 3 min

Testosterone therapy in postmenopausal women linked to sharply higher cardiovascular risk

OncLive · 3 min

FDA approves dostarlimab as first immunotherapy for locally advanced rectal cancer, letting most patients skip chemo and surgery

Everything on Curie.MD

NeurologyPlay & LearnLearn what’s new in your field, a few minutes at a time.Start learning CardiologyCalculatorsEnter the case once. See every relevant score, side by side.Open a calculator All fieldsDaily GamesThree new clinical puzzles every morning.Play today

Get Curie’s Weekly Dose

What changed in clinical practice, policy, and coverage, and what it means for your patients.

Subscribe free Free. Weekly. Unsubscribe anytime.